The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Tumor heterogeneity revealed by drug-induced apoptosis (MiCK) assays in lung cancer.
Dennis A. Wigle
No relevant relationships to disclose
Cary A. Presant
Employment or Leadership Position - DiaTech Oncology
Consultant or Advisory Role - DiaTech Oncology
Stock Ownership - DiaTech Oncology
Research Funding - DiaTech Oncology
Allan Hallquist
Employment or Leadership Position - DiaTech Oncology
Mathieu Perree
Employment or Leadership Position - DiaTech Oncology
James Rutledge
Consultant or Advisory Role - DiaTech Oncology
Julian R. Molina
No relevant relationships to disclose